Genenta Science S.P.A. ADR (GNTA) Stock Price, Quote & News

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...

Industry: Biotechnology

Sector: Healthcare

Phone: 39 02 26434681

Website: www.genenta.com

Address:

Via Olgettina No. 58, Milan, Italy

DARKP00L Apr. 23 at 11:27 AM

$GNTA 07:13 on Apr. 23 2026 Genenta Science Signs Definitive Agreements With Sòphia High Tech; Genenta Expects To Fund Total Of €6 Million In Two Tranches #tradeideas

0 · Reply

Paraboljoker Apr. 23 at 11:16 AM

Watchlist Low Float Momentum Rotation 🔥 Fresh PR Catalysts & Continuation Plays Loading $BURU Leading the charge right now! Tight share structure with volume exploding — this one is waking up strong and looking primed for a serious leg up. Heavy eyes locked in, could easily surprise to the upside this week $GNTA 51% stake PR just landed 🔥 Micro float ready to go parabolic on any follow-through volume. These kind of stake/news catalysts have history of sending these names flying — keep this one on maximum radar! $CTNT Offer close PR dropping any moment 👀 Recent action has been building nicely and once that news hits it’s game on for the next explosive leg. Strong hands accumulating quietly — don’t miss the breakout $AKAN Alerted yesterday and already delivered 200%+ monster move with nice profits taken 🏦 $CXAI AI sector bottom forming beautifully with solid PR dropped yesterday. This one is waking up at the perfect time — continuation setup looks very clean. AI narrative is back in play and CXAI is sitting right in the sweet spot Let's ride🃏

0 · Reply

Bcity Apr. 22 at 8:55 PM

$GNTA consolidated nicely at these levels.

0 · Reply

Fakhrul123 Apr. 13 at 6:09 PM

$GNTA keep drowning!

0 · Reply

SmokeyPalaceTrades Mar. 31 at 4:24 AM

$GNTA binding with sophia tech, not bad

0 · Reply

DarkSonar Mar. 27 at 1:20 PM

$GNTA Obscure little stock. Liking the news today but will just monitor it for now. 🔬

0 · Reply

Mapago Mar. 27 at 11:08 AM

$GNTA Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

0 · Reply

Disrupter Mar. 24 at 9:06 AM

$GNTA Identify crisis stock with active filing

1 · Reply

SilentRider1 Mar. 4 at 7:14 PM

$GNTA After rs

0 · Reply

Fakhrul123 Feb. 25 at 5:28 AM

$GNTA go back to $4

1 · Reply

Genenta signs Definitive Agreements with Sophia High Tech

Mar 27, 2026, 5:00 AM EDT - 4 weeks ago

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

Mar 24, 2026, 3:27 AM EDT - 4 weeks ago

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Mar 13, 2026, 5:00 AM EDT - 6 weeks ago

Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Feb 27, 2026, 4:00 AM EST - 2 months ago

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

Jan 27, 2026, 12:45 PM EST - 3 months ago

Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments

Jan 27, 2026, 3:00 AM EST - 3 months ago

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Dec 19, 2025, 2:30 AM EST - 4 months ago

Genenta Science Provides Update on CEO Ownership

Nov 24, 2025, 4:00 AM EST - 5 months ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Oct 26, 2025, 8:30 PM EDT - 6 months ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Oct 24, 2025, 4:00 AM EDT - 6 months ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Jul 1, 2025, 5:00 AM EDT - 10 months ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

May 8, 2025, 7:00 AM EDT - 1 year ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 7, 2025, 7:00 AM EDT - 1 year ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Apr 15, 2025, 5:00 AM EDT - 1 year ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

Mar 19, 2025, 9:28 AM EDT - 1 year ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Jan 28, 2025, 8:01 AM EST - 1 year ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Jan 9, 2025, 6:00 AM EST - 1 year ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 8, 2025, 3:17 PM EST - 1 year ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

May 6, 2024, 6:25 AM EDT - 2 years ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

Feb 8, 2024, 5:00 AM EST - 2 years ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Jul 28, 2023, 3:00 AM EDT - 2 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jun 29, 2023, 7:00 AM EDT - 3 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Mar 2, 2023, 6:45 AM EST - 3 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Nov 7, 2022, 8:05 AM EST - 3 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Oct 24, 2022, 7:30 AM EDT - 3 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Investor Conferences

Jul 25, 2022, 6:00 AM EDT - 4 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

May 13, 2022, 7:30 AM EDT - 4 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 9, 2022, 7:30 AM EDT - 4 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 4, 2022, 4:30 PM EDT - 4 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 7:30 AM EDT - 4 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 2, 2022, 4:30 PM EDT - 4 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Apr 27, 2022, 7:30 AM EDT - 4 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 20, 2022, 7:30 AM EDT - 4 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Dec 17, 2021, 4:15 PM EST - 4 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 14, 2021, 10:36 PM EST - 4 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

DARKP00L Apr. 23 at 11:27 AM

$GNTA 07:13 on Apr. 23 2026 Genenta Science Signs Definitive Agreements With Sòphia High Tech; Genenta Expects To Fund Total Of €6 Million In Two Tranches #tradeideas

0 · Reply

Paraboljoker Apr. 23 at 11:16 AM

0 · Reply

Bcity Apr. 22 at 8:55 PM

$GNTA consolidated nicely at these levels.

0 · Reply

Fakhrul123 Apr. 13 at 6:09 PM

$GNTA keep drowning!

0 · Reply

SmokeyPalaceTrades Mar. 31 at 4:24 AM

$GNTA binding with sophia tech, not bad

0 · Reply

DarkSonar Mar. 27 at 1:20 PM

$GNTA Obscure little stock. Liking the news today but will just monitor it for now. 🔬

0 · Reply

Mapago Mar. 27 at 11:08 AM

$GNTA Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

0 · Reply

Disrupter Mar. 24 at 9:06 AM

$GNTA Identify crisis stock with active filing

1 · Reply

SilentRider1 Mar. 4 at 7:14 PM

$GNTA After rs

0 · Reply

Fakhrul123 Feb. 25 at 5:28 AM

$GNTA go back to $4

1 · Reply

BillionerOfKing Feb. 21 at 6:16 PM

$GNTA Current Stock Price: $1.00

0 · Reply

_Thombo_ Feb. 20 at 8:52 PM

$GNTA Looks like 😊

0 · Reply

OfficialStocktwitsUser Feb. 17 at 8:48 PM

$GNTA RSI: 18.40, MACD: -0.1597 Vol: 0.25, MA20: 1.06, MA50: 1.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

FactorMomentum Feb. 17 at 1:22 PM

$GNTA Pre-revenue biotech; early-stage.

0 · Reply

FlowFinance Feb. 9 at 3:45 PM

$GNTA Gene therapy biotech; carries the extreme risks of the modality.

2 · Reply

TaliscaXi Feb. 9 at 7:52 AM

$UOKA CAN’t wait to see this hit 2.5 $ Go PIVOTING !!!!!!!!!!!!!! $GNTA $TNON $CCHH $OFRM

0 · Reply

123MONEYGUY Feb. 3 at 8:07 PM

$GNTA IT FAILED TO ATTRACT INSTITUTIONAL TRADERS

0 · Reply

theBigDollarski Feb. 3 at 7:41 PM

$GNTA good thing they announced that strategic transformation before the stock really fell apart.....

0 · Reply

123MONEYGUY Feb. 3 at 6:28 PM

$GNTA garbage disposal

0 · Reply

Market Cap	16.84M
Revenue (ttm)	0.00
Net Income (ttm)	-7.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	24,307
Avg Vol	81,220
Day's Range	N/A - N/A
Shares Out	23.59M
Stochastic %K	57%
Beta	0.71
Analysts	Strong Sell
Price Target	$7.00